Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.
about
The safety of pharmacologic options for the treatment of persons with hemophilia.Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation.Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.Viral safety of haemophilia treatment products.New-generation recombinant factor concentrates: bridge to gene therapy.Treatment of hemophilia B: focus on recombinant factor IX.Human erythrovirus B19 and blood transfusion - an update.Parvovirus B19 in anemic liver transplant recipientsParvovirus B19V DNA contamination in Chinese plasma and plasma derivativesLaser welding with albumin-based solder: experimental full-tubed skin graft urethroplasty.Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reactionClinical use of factor VIII and factor IX concentratesA linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion.Management of pregnancy, labour and delivery in women with inherited bleeding disorders.The modern treatment of haemophilia: a narrative reviewHaemophilia B: current pharmacotherapy and future directions.Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.Current management of hemophilia B: recommendations, complications and emerging issues.Current Practice in the Treatment of Haemophilia.Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.Reducing the infectivity of blood components--what we have learned.Advances in photochemical approaches for blood sterilization.Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A.The genomic and seroprevalence of human bocavirus in healthy Chinese plasma donors and plasma derivatives.Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs.German blood scandal.Fresh frozen plasma. Viral inactivation may be false reassurance.Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood CD34+ cells.Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses.Virucidal treatment of blood protein products with UVC radiation.Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.Long-term follow up of patients treated with intermediate FVIII concentrate BPL 8Y.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.A post-marketing safety and efficacy assessment of a monoclonal antibody purified high-purity factor VIII concentrate.Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B.Impact of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in Japanese blood donors.Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.Removal of parvovirus B19 from hemoglobin solution by nanofiltration.
P2860
Q30249200-ECB16CB3-3B74-4A90-A202-AFF8B1BAA526Q33338991-057B2151-36B6-4F62-83C3-74408975C755Q33815761-2D1429C7-7D16-4BEE-A31F-20878CFA7DE3Q34087439-152A9EDA-85C2-4D58-A573-44B9C1FD7D17Q34176033-059E916E-B886-4496-8104-29FE530BC52EQ34329068-D2D64AB8-8429-4DAD-A1BC-C457F87B0602Q34660084-1951F0D2-1D91-46C3-9A81-990C563E362BQ35228305-46F6FB5F-8C5B-409C-B3B5-22743BFA47D3Q36448471-7BB95BB2-BE86-4419-B030-BE7C819FDAA8Q36816104-46AB4EF0-6D38-4339-BF33-F17610DBE9C6Q37064067-04D4941C-C2A4-49A5-95BA-87B67A635A33Q37370356-C427F987-C77B-41AC-9ED1-8687ED800CC9Q37398336-995A8517-A117-4A92-9D67-12244EE4D255Q37892650-CBDF131F-9047-4F29-9596-4C6C0647F51EQ38025882-F9B5CFA9-46C0-4D13-B94E-D3A4F0AA083BQ38040458-425B6A66-C7DD-48B9-A12B-754546EAA194Q38151843-BE94D888-D571-424E-A4EC-C159EE7146CDQ38238972-B4D0FAAF-6AB1-412E-B919-A7A1657F80AFQ38894036-16BA6AEF-0C92-4E2F-8712-20B74D4E45E0Q38912064-7A8F63E0-4493-442B-BCD7-6E782D76F09EQ40505351-36F276F9-72D6-4877-AF65-A6649B275559Q40951082-88966B86-2AAA-4CDF-898A-F1BA4BD355A8Q41684827-4CD1BD20-AC76-41A2-B80D-4815CB37FC93Q42204512-3B758184-A763-4700-AE50-2F37A472AB74Q42236600-1D39940D-9A15-4B95-B238-0F53666A1945Q43047300-0C93EA2B-1070-401B-B00A-E14690F7BF84Q43150398-C856C9FD-1551-40C0-8EDF-21027BFF0947Q43151323-DA7B5A5A-ADB1-4142-AC6C-847E4CF17556Q43584966-251688FF-A6FC-43BF-93E9-1C025ADF165BQ43799305-39FFC52D-7FD9-484A-9188-4740521F96DCQ45239152-89E24F4D-5642-49B5-A9A7-CF57050ED18FQ45742848-10670389-E9E1-4FA3-A730-2DA2D508357FQ45855156-70EE53A7-1663-44CC-A2DC-877AFEB1E731Q45865134-B7C50A59-8C23-4576-9FAB-414246E53F2CQ45886474-80FC3D7F-5FCF-4AE4-A9AB-ADB269899516Q45887091-38B7E6F9-0521-4F90-8A66-3A4378050454Q50500602-998F044D-C4D3-4F83-9E0D-D3B3E04B5B3AQ51905617-1A01F37B-F4E1-475D-9628-6D9F0DBD5FD0Q53237311-1B621435-FB02-462F-878C-ED3BAFD39224Q54035277-AB977974-1579-4D89-81F3-795012748153
P2860
Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@en
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@nl
type
label
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@en
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@nl
prefLabel
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@en
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@nl
P2093
P356
P1476
Human parvovirus B19 infection ...... ated factor VIII concentrates.
@en
P2093
P2860
P304
P356
10.1002/AJH.2830390315
P577
1992-03-01T00:00:00Z